Re: Look for second hand licences for Toad 7.2.0.0 and PowerAMC 8.0.1.2.7.5

That they are copies is irrelevant on two counts. First because the cost of bringing a copy to market is not that much less than bringing a new drug to market. You still have to file INDs and NDAs and go through the clinical and legal work.

It is irrelevant on a second count to ... no doubt the same could be said for Chevys and Fords. Or for MacDonalds and Burger King. Or for Oracle and SQL Server. Or for Safeway and Albertsons.

Daniel Morgan

Keith Boulton wrote:

> A reasonable point, except that many of these products are "me too" copies
> of existing drug which are no more effective than existing drugs.
>
> There are also paradoxes involved like the introduction of direct
> advertising to patients which has driven up all drug-companies' advertising
> costs without at first sight being better off for it.
>
> Of course a free market tends to the most economically efficient mechanisms,
> but patents are themselves are a deliberate obstacle to the free market in
> order to address a market failure and it makes sense to ensure that such a
> mechanism is not being abused and if other market limiting mechanisms might
> be useful.
>
> Having said that, drug companies appear to have a much stronger case for
> patent protection than the ludicrous patents that seem to becoming prevalent
> in IT.
>
> Noodles <noodles_at_aol.com> wrote in message
> news:20020209063624.16137.00000441_at_mb-fq.aol.com...
> > {Kind of off-topic...}
> >
> > Dan,
> >
> > An average research investment for a U.S. product to get to market is $850
> > million dollars. One reason the marketing costs are very high because of
> > limited patented protection. Consequently, time is limited and you can't
> wait
> > around until the medical community decides to prescribe your product to
> one of
> > their patients. Once the patent protection is up, the generic companies
> will
> > start undercutting your price. A company must recoup all of its costs
> within
> > the patent life time just to remain solvent, let alone generate profits
> and
> > growth.
> >
> > [ Yes, I do work for a large pharmaceutical company so please filter out
> any
> > potential bias]
> >
> > Cliff
> >
> >
Received on Sat Feb 09 2002 - 07:05:40 CST